|Security||BETR / Amplify Snack Brands, Inc. (03211L102)|
|Industry||Food And Kindred Products|
|Institutional Shares||9,206,014 - 12.00%|
|Common Shares Outstanding||76,745,948 shares (as of 2017-09-30)|
|Institutional Value||$ 72,211,000 USD|
Institutional Stock Ownership and Shareholders()
Amplify Snack Brands, Inc. (NYSE:BETR) has 11 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,206,014 shares.
Largest shareholders include
Discovery Group I, LLC, Janus Capital Management Llc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., Century Capital Management, LLC, Holland Capital Management Llc, BlackRock Investment Management, LLC, Independent Portfolio Consultants, Inc., BlackRock Advisors LLC, and BlackRock Group LTD.
Amplify Snack Brands, Inc. (NYSE:BETR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|BlackRock Advisors LLC||30,079||15,355||-48.95||487||135||-72.28|
|HOLLAND CAPITAL MANAGEMENT LLC||138,827||138,827||0.00||1,223||1,166||-4.66|
|BlackRock Group LTD||21,533||10,138||-52.92||349||89||-74.50|
|Independent Portfolio Consultants, Inc.||63,370||56,747||-10.45||532||547||2.82|
|TA XI, L.P.|
|GLG Partners LP||22,394||0||-100.00||159||0||-100.00|
|BlackRock Investment Management, LLC||108,656||109,484||0.76||1,760||965||-45.17|
|BlackRock Fund Advisors||752,302||879,951||16.97||12,187||7,752||-36.39|
|FNY Partners Fund LP||Call||113||0||-100.00||1||0||-100.00|
|FNY Partners Fund LP||6,100||0||-100.00||73||0||-100.00|
|JANUS CAPITAL MANAGEMENT LLC||0||1,829,763||0||15,370|
|ISRAEL DISCOUNT BANK OF NEW YORK /GFN||1,215||11|
|BlackRock Institutional Trust Company, N.A.||602,132||851,466||41.41||9,755||7,501||-23.11|
|Hutchin Hill Capital, LP||249,695||0||-100.00||1,770||0||-100.00|
|TA ASSOCIATES, L.P.||0||0||0||0|
|Discovery Group I, LLC||3,487,952||4,918,795||41.02||33,624||34,874||3.72|
|Century Capital Management, LLC||271,368||394,273||45.29||2,279||3,801||66.78|
12h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
13h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
13h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
Consumer stocks are on fire so far in 2018 — the Consumer Discretionary Select SPDR ETF (NYSEARCA:XLY) is up 14% year to date through August 13, double the performance of the S&P 500 — and that’s got Goldman Sachs (NYSE:GS) singing the praises of 7 companies that include a hotel chain, food services business, a casino operator, and several more. (21-0)
The Hershey Company (HSY - Free Report) is scheduled to release second-quarter 2018 results on Jul 26. We expect the company to continue gaining from its cost-saving and productivity improvement efforts. Focus on innovation and brand enhancing initiatives are also likely to drive Hershey’s performance amid hurdles. (4-0)
We like Hershey's brand, competitive position, pricing power, and ability to extract greater levels of profitability each and every year. (9-0)
Just 25% of S&P 500 companies have two or more women on their board of directors. For women looking to become a CEO one day, it’s a big problem. (26-0)
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com (19-0)
as of ET